Companies Join Forces to Address Urgently Needed Quality Control of CRISPR Genome-editing

COBO Technologies and Cardea Bio partner to bring solutions to challenges with the precision of Genome editing. The partners have agreed to co-develop and market a portfolio of CRISPR QC products and services for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the parties aim to develop a COBO branded QC device based on Cardea’s CRISPR-Chip™ QC technology for use before and after genome-editing in the pre-clinical setting.

(PRWeb January 21, 2020)

Read the full story at https://www.prweb.com/releases/companies_join_forces_to_address_urgently_needed_quality_control_of_crispr_genome_editing/prweb16848818.htm

For more information, please visit
https://www.prweb.com/releases/companies[...]nome_editing/prweb16848818.htm

You need to login to post comments.

Feed last updated 2024/04/30 @5:04 AM

0 COMMENTS:

VOCAPIA and SYSTRAN demonstrate an automated speech translation solution at EUROSATORY 2016 - GlobeNewswire (press release) views: 1526

Instagram is adding automatic in-app text translation - The Verge views: 1520

Here’s a ‘Brand-New’ Massive Multilingual Dataset for Machine Translation views: 1503

F.A.Q. | Terms and conditions